Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu, according to the Centers for Disease Control and Prevention (CDC).

Sage Therapeutics has left its view of Biogen's recent takeover bid in little doubt – it has just filed a lawsuit seeking to block the deal. Specific details of the lawsuit are not yet available ...

AstraZeneca and Daiichi Sankyo have claimed FDA approval for a second antibody-drug conjugate (ADC) for breast cancer, hoping to build on the success of a partnership that already spawned a ...

While there have been many significant advances in healthcare in the past 25 years, including new treatments for cancer recurrence, more effective disease maintenance strategies, more precise and ...

Biogen's treatment for neurodegenerative disorder spinal muscular atrophy (SMA) Spinraza has come under pressure in an increasingly competitive market, but the company hopes a new high-dose ...

Bayer is preparing to start a phase 3 trial of its cell therapy candidate bemdaneprocel for Parkinson's disease after discussing phase 1 results with the FDA, while its experimental gene therapy ...

People who take weight-loss drugs based on GLP-1 receptor agonists seem to have reduced risk for a litany of diseases, including Alzheimer's, but an increase in some other conditions like kidney ...

Odyssey Therapeutics and Sionna Therapeutics have filed to carry out initial public offerings (IPOs) on the Nasdaq, taking the number in the newly-filed queue to four since the start of the year.

Swiss antibiotic developer BioVersys has launched an initial public offering, hoping to raise CHF 80 million ($88 million) to advance its pipeline of drug candidates for infections plagued by ...

Phil Johnson started about four months ago as chief commercial officer at Evidation. He sat down on the sidelines of JP ...

The report suggests that USAID could have seen its 10,000-strong workforce reduced to just 300, with the new figure emerging ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare sector ...